- Open Access
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
Journal of Experimental & Clinical Cancer Research volume 35, Article number: 70 (2016)
- The Erratum to this article has been published in Journal of Experimental & Clinical Cancer Research 2016 35:95
Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for treatment of breast and NSCLC xenograft tumors in mouse models and explored a treatment strategy by combination of Zt/g4-DM1 with chemotherapeutics to achieve the maximal therapeutic activity.
Mouse monoclonal antibody Zt/g4 (IgG1a/κ) specific to human RON was conjugated to DM1 via thioether linkage to form Zt/g4-DM1 with a drug-antibody ratio of 4:1. Several breast cancer and NSCLC cell lines, expressing different levels of RON, were used as the model. Immunofluorescence was used to determine Zt/g4-induced RON internalization. Flow cytometric analysis and cell viability assay were used to determine the effect of Zt-g4-DM1 on cell cycle and death. Mouse xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of Zt/g4-DM1 alone or in combination with chemotherapeutics.
In vitro, Zt/g4 treatment of breast cancer and NSCLC cells rapidly induced cell surface RON internalization, which results in intracellular delivery of DM1 sufficient to arrest cell cycle at G2/M phase, reduce cell viability, and cause massive cell death. In mouse tumor xenograft models, Zt/g4-DM1 at 20 mg/kg in a Q12 × 2 regimen effectively blocked breast cancer and NSCLC cell- mediated tumor growth. More than 95 % inhibition of tumor growth among three tumor xenograft models tested was achieved according to the measured tumor volume. The minimal dose to balance the tumor growth and inhibition (tumoristatic concentration) was established at 2.02 mg/kg for H2228, 1.94 mg/kg for H358 cell, and 6.25 mg/kg for T-47D cell-mediated xenograft tumors.
Zt/g4 is highly effective in RON-directed drug delivery for targeted inhibition of NSCLC cell-derived tumor growth in mouse xenograft models. This work provides the basis for clinical development of humanized Zt/g4-DM1 for potential cancer therapy in the future.
Antibody-directed drug delivery in the form of antibody-drug conjugates (ADC) is a promising anti-cancer strategy [1–3]. Structurally, ADC is formed by a target-specific monoclonal antibody (mAb) conjugated with a highly potent toxic drug through a versatile linker at a precise drug- antibody ratio [1–3]. Since 2012, two ADCs, ado-trastuzumab emtansine (T-DM1, Kadcyla, Roche-Genentech) and brentuximab vedotin (SGN-35, Adcetris, Seattle Genetics) have been approved for targeted therapy of breast cancer (BC) and lymphomas, respectively [4–7]. T-DM1 is specific to HER2 expressed by BC . SGN-35 targets the CD30 antigen, a cell surface antigen expressed by Hodgkin’s and other subsets of lymphoma cells [6, 7]. Currently, ADCs employing different antibodies targeting different cell surface proteins such as PSMA [8, 9]. Ephrin-A4 , CD78B [11, 12], Trop-2 , and LY6E  are under intensive study in preclinical models. More than 30 ADCs are under clinical trials (www.clinicaltrials.gov). Thus, ADCs represent a promising therapeutic modality for the clinical management of cancer.
The RON receptor tyrosine kinase is a member of the MET proto-oncogene family implicated in the pathogenesis of BC and non-small cell lung cancer (NSCLC) [15–20]. Immunohistochemical staining using specific antibodies has shown increased RON expression in primary BC and NSCLC samples [21–24], which results in aberrant signaling facilitating cancerous cell growth, migration, and invasion . Overexpression of RON also has been considered as a potential drug target for cancer treatment [25–29]. Currently, RON-specific therapeutics including tyrosine kinase inhibitors (TKI) and therapeutic monoclonal antibodies (TMA) have been developed and validated in various preclinical cancer models [25–29]. Clinical trials using RON-specific TKIs and TMAs are also under investigation (www.clinicaltrials.gov). Evidence accumulated from various studies showed that inhibition of RON has the therapeutic effects on cancer cell growth, migration, and survival [25–29]. However, the efficacy of RON- specific TKIs and TMAs is relatively low with only partial tumor inhibition [25–29]. The inability of anti-RON TKIs and TMAs to achieve the maximal effect is mainly due to the lack of complete addiction of cancer cells to RON signaling for growth and survival . Thus, it is critical to improve the drug efficacy for the success of RON-targeted cancer therapy.
For the last several years, we have focused on anti-RON mAb-directed drug delivery for targeted cancer therapy [25, 30–32]. Several mAbs specific to human RON were produced and selected for their suitability for RON-targeted drug delivery [25, 30–32]. Zt/g4 is one of the anti- RON mAbs chosen for RON-targeted drug delivery [25, 33, 34]. Zt/g4 recognizes an antigenic epitope located in the Sema domain of the RON extracellular sequence and induces rapid internalization of the cell surface RON molecules [25, 33, 34]. This property makes Zt/g4 a suitable candidate to conjugate with DM1 to form anti-RON ADC Zt/g4-DM1 for targeted drug delivery. In this study, we used BC and NSCLC cells as the experimental models to determine the effectiveness of Zt/g4 in induction of RON internalization by a panel of BC and NSCLC cell lines expressing different levels of RON. The cytotoxic activity of anti-RON ADC Zt/g4-DM1 was evaluated in both in vitro cell lines and in vivo xenograft tumor models. Moreover, we explored a treatment strategy by combination of Zt/g4-DM1 with chemotherapeutics to achieve the maximal therapeutic activity against BC and NSCLC xenograft tumors. We believe that results from these studies confirm the potentials of anti-RON ADC for BC and NSCLC treatment and establish the foundation for development of humanized anti-RON ADC.
Cell lines and reagents
Human BC cell lines MCF-7, DU4475, MDA-MB-231, T-47D, and NSCLC cell lines H1993, H2228, and H358 were from ATCC (Manassas, VA). Mouse anti-RON mAbs Zt/g4, Zt/c1 and rabbit anti-RON IgG antibodies were as previously described . Goat anti-mouse IgG labeled with FITC or rhodamine was from Jackson ImmunoResearch (West Grove, PA).
Generation of Zt/g4-DM1
Zt/g4 was conjugated with DM1 at a drug-antibody ratio of 4:1 by through the linker SMCC as previously described [1, 4, 25, 35]. Control mouse IgG conjugated with DM1 (CmIgG-DM1) was used as the control. The Zt/g4-DM1 was verified by HIC using a Varian Prostar 210 Quaternary HPLC system coupled with a TSK butyl-NPR 4.6 × 3,5 column (Tosoh Biosciences (Prussia, PA) .
Assay for cell surface RON expression
Cell surface RON was quantitatively determined by the immunofluorescence assay using QIFKIT® reagents from DAKO (Carpentaria, CA). Briefly, cells (1 × 106 cells per ml in PBS) were treated with Zt/g4 at saturating concentrations followed by incubation in parallel with the QIFIKIT® beads and goat F(ab’)2 F0479. After establishing a calibration curve, the number of RON receptor on the cell surface was determined by interpolation following the manufacturer’s instruction.
Analysis of cell cycle
BC and NSCLC cells (1 × 106 cells per dish) were treated with 5 μg/ml of Zt/g4-DM1 at 37 °C for 24 h. Cells were then labeled with propidium iodide followed by Accuri flow cytometric analysis. Cell cycle changes were determined by measuring DNA contents as previously described .
Western blot analysis
Cellular proteins (50 μg per sample) were separated in an 8 % SDS- PAGE under reduced conditions. Cellular proteins such as PARP were detected in Western blotting using specific antibodies. Membranes also were reprobed with anti-actin antibody to ensure equal sample loading .
Detection of intracellular RON
BC and NSCLC cells at 1 × 105 cells per well in a 6-well plate were treated with 5 μg/ml of Zt/g4-DM1 for various times followed by goat anti-mouse IgG coupled with FITC . Nuclear DNAs were stained with 4′,6-diamidino-2-phenylindole (DAPI) . Cellular immunofluorescence was observed under an Olympus microscope equipped with DUS/fluorescent apparatus.
Assays for cell viability and cell death
Cell viability 96 h after Zt/g4-DM1 treatment was determined by the MTT assay [31, 36]. Percentages of viable or dead cells were determined using the trypan blue exclusion assay as previously described [31, 36].
Mouse xenograft tumor model and anti-RON ADC treatment
All experiments on mice were approved by the TTUHSC Institutional Animal Care Committee. Female athymic nude mice at 6 weeks of age (Taconic, Cranbury, NJ) were injected with 5 × 106 cancer cells in the subcutaneous space of the right flank as previously described [25, 33]. Mice were randomized into different groups (five mice per group). Treatment began when tumors reaches a mean tumor volume of ~100 mm3. To evaluate the Zt/g4-DM1 efficacy, mice were injected with Zt/g4- DM1 at 20 mg/kg in a Q12 × 2 regimen. Tumor growth was observed up to 52 days. In study of Zt/g4-DM1 in combination with gemcitabine, tumor-bearing mice were treated with gemcitabine alone at 60 mg/kg in a Q4 × 4 schedule , Zt/g4-DM1 alone at 10 mg/kg in a Q8 × 2 schedule, or their combinations with above described concentrations. Tumor volumes were measured every 4 days and calculated as previously described [24, 25]. Animals were euthanized when tumor volumes exceeded 2000 mm3 or if tumors became necrotic or ulcerated through the skin.
GraphPad 6 software was used for statistical analysis. Results are shown as mean ± SD. The data between control and experimental groups were compared using Student t test. Chi-squared analysis was used for correlational study. Isobolograms were used for analysis of synergism in drug combination studies. Statistical differences at p <0.05 were considered significant.
Induction by Zt/g4-DM1 of cell surface RON internalization
To study the effect of Zt/g4 on RON internalization, we first determined the number of RON molecules expressed on cell surface using the QIFKIT® fluorescence-based quantitative method (Fig. 1a). The calculated RON molecules on the surface of a single cell was 14,841 ± 266 for DU4475, 8185 ± 256 for MDA-MB231, 15,756 ± 314 for T-47D, 2152 ± 208 for H1993, 10,207 ± 278 for H2228, and 15,286 ± 366 for H358 cells, respectively. Specific binding was not observed in MCF-7 cells. The binding profiles of DM1-conjugated Zt/g4 were shown in Fig. 1b. Mouse IgG and its DM1 conjugates (CmIgG-DM1) were used as the control. When antibodies were used at 5 μg IgG per ml, the RON binding profile of Zt/g4-DM1 was similar to that of free Zt/g4 among seven cell lines tested, suggesting that DM1 conjugation does not impair the binding capability of Zt/g4.
The effect of Zt/g4-DM1 on RON internalization is shown in Fig. 1c. Zt/g4-DM1 treatment caused a progressive reduction of cell surface RON in a time-dependent manner in all six cell lines tested. Less than 20 % of RON remained on the cell surface after a 36 h treatment. The effect of Zt/g4-DM1 on RON expressed by MCF-7 cells was minimal. We defined the time required to have a 50 % reduction in cell surface RON as the internalization efficacy (IE50). The calculated IE50 values were >100 h for MCF-7, 14.32 h for DU4475, 11.71 h for MDA- MB-231, 23.46 h for T-47D, 11.65 h for H1993, 7.47 h for H358, and 9.84 h for H2228 cells (Fig. 1c). These results indicate that Zt/g4-DM1 differentially induces RON internalization in different cancer cells. Immunofluorescence analysis confirmed Zt/g4-DM1-induced RON internalization in four selected cell lines (Fig. 1d and e). RON was detected on the cell surface at 4 °C. The internalization occurred at 37 °C after Zt/g4-DM1 treatment. Cytoplasmic RON was co-localized with LAMP1 in both BC and NSCLC cells. Thus, results from Fig. 1 demonstrate that Zt/g4-DM1 effectively induces RON internalization by BC and NSCLC cells.
Effect of Zt/g4-DM1 on cell cycle, growth, and death of BC and NSCLC cells
The effect of Zt/g4-directed DM1 delivery on cell cycle was shown in Fig. 2a. The changes in cell cycle were observed as early as 6 h after addition of Zt/g4-DM1, which features a significant reduction in G0/G1 phase, a decrease in S phase, and a dramatic increase in G2/M phase. Quantitative measurement of cell cycle changes is shown in Table 1. Clearly, Zt/g4-targeted delivery of DM1 has a profound effect on cell cycle by BC and NSCLC cells overexpressing RON.
We next studied the effect of Zt/g4-DM1 on viability of BC and NSCLC cells using the MTT assay. CmIgG-DM1 was used as the control. We first determined sensitivities of each cell line to free DM1. The calculated IC50 values were 98.29 ± 2.89 nM for MCF-7; 12.42 ± 2.82 nM for DU4475; 23.45 ± 3.48 nM for MDA-MB-231; 7.24 ± 1.45 nM for t-47D; 4.16 ± 0.38 nM for H1993; 7.13 ± 0.51 nM for H358; and 6.59 ± 0.44 nM for H2228, respectively. We then studied the effect of Zt/g4-DM1 on cell viability. A significant reduction in cell viability was observed in a dose-dependent manner in all tested cell lines expressing high levels of RON (Fig. 2b). The IC50 of Zt/g4-DM1 was 2.86 μg/ml for DU4475, 7.74 μg/ml for MDA-MB-231, 2.29 μg/ml for T- 47D, 5.13 μg/ml for H2228, and 2.44 μg/ml for H358 cells, respectively. MCF-7 cells were not sensitive to Zt/g4-DM1. Only a 12 % reduction in cell viability was observed after cells were treated with 20 μg/ml of Zt/g4-DM1. Also, H1993 cells expressing low levels of RON were only slightly sensitive to Zt/g4-DM1. A 29 % reduction in cell viability was documented after cells were treated with 15 μg/ml of Zt/g4-DM1. The kinetic effect of Zt/g4-DM1 on cell viability was studied using H2228 and H358 cells as the model (Fig. 2c). Zt/g4-DM1 caused a time-dependent reduction in cell viability in both cell lines tested. Thus, Zt/g4-DM1 is able to reduce cell viability in both dose- and time-dependent manners in cancer cells overexpressing RON.
Observation of cell morphology under a microscope indicated a massive cell death after Zt/g4-DM1 treatment in BC and NSCLC cells overexpressing RON with more than 50 % cell death after a 96 h treatment (Fig. 3a and b). The calculated IC50 values were 2.02 ± 0.16 μg/ml for DU4475, 1.80 ± 0.10 μg/ml for MDA-MB-231, 6.12 ± 0.16 μg/ml for T-47D, 1.78 ± 0.27 μg/ml for H358, and 1.96 ± 0.21 μg/ml for H2228 cells. Western blot analysis of the PARP activation, a cellular apoptosis indicator [38, 39] is shown in Fig. 3c. PARP fragments were evident from BC and NSCLC cells in both time and dose-dependent manners after Zt/g4-DM1 treatment. Thus, Zt/g4-DM1 not only arrests cell cycles and decreases cell viability, but also reduces viable cell numbers and induces massive apoptotic cell death.
Correlations in vitro between the level of RON expression and the efficacy of Zt/g4-DM1 on cell viability
A comparison between the efficacy of Zt/g4-DM1 (cell viability IC50 value) and the number of RON receptors per cell is shown in Fig. 4. The increased efficacy of Zt/g4-DM1 as evident by decreased IC50 values is correlated with the number of RON molecules expressed on the cell surface. It appeared that the minimal number of cell-surface RON molecules required for Zt/g4-DM1 to achieve a 95 % reduction in cell viability (EC95) is around 10,000 molecules per cell. A decrease in the level of RON receptors per cell correlated proportionally with the diminished efficacy of Zt/g4-DM1. Thus, cancer cells expressing ~10,000 RON molecules on cell surface per cell appears to be required for Zt/g4-DM1 in vitro to show the maximal activity.
Therapeutic activity of Zt/g4-directed DM1 delivery in mouse xenograft tumor model
The goals of the in vivo study were to validate the efficacy of Zt/g4-DM1 and to determine the tumoristatic concentration (TSC). The TSC is a dose that reaches a balance in vivo between the tumor growth and inhibition. To this end, mouse xenograft tumor models of H1993, H288, H358, and T-47D cells were established. Xenograft models for MDA-MB-231 and DU4475 cells were unable to be established. Zt/g4-DM1 at 20 mg/kg with a Q12 × 2 schedule was used for in vivo studies, which was designed according to our previous studies and the terminal half-life (t½: 6.01 days) of Zt/g4-DM1 (25). As shown in Fig. 5a, xenograft tumors initiated by H1993 cells expressing only 2152 RON receptors per cell were insensitive to Zt/g4-DM1. In contrast, Zt/g4- DM1 was highly effective in delaying tumor growth caused by H2228, H358 and T-47D cell lines. The effect of Zt/g4-DM1 in vivo was long lasting. At day 40, the tumor growth inhibition was 96.12 % for H2228 and 95.66 % for H358 cell xenograft tumors. For T-47D cell-initiated tumors, Zt/g4-DM1 showed a tumor growth inhibition at 86.4 % at day 36.
A comparison of tumor weight between the control and Zt-g4-DM1 treated group at the end of experiments was shown in Fig. 5b. In Zt/g4-DM1-treated H1993 xenograft tumors, we did not observe a statistical difference in tumor weight between the control and experimental group, confirming that Zt/g4-DM1 has no effect on tumors expressing low levels of RON. In contrast, Zt/g4-DM1 was effective in inhibition of tumors expressing high levels of RON. Although tumors from Zt/g4-DM1-treated H2228 and H358 cell groups were collected 8 days later (day 44 for control mice versus day 52 for experimental animal), a significant reduction in average tumor weight was still observed for H358 (82.58 %) and H2228 (90.71 %) cell-derived xenograft tumors. Similarly, significant reduction in average tumor weight (86.57 %) also was documented in T-47D cell derived xenograft tumors. Thus, Zt/g4-DM1 at 20 mg/kg in the Q12 × 2 regimen is effective in inhibition of xenograft tumor growth initiated by H2228, H358 and T- 47D cells.
We calculated the TSCs based on the terminal half-life of Zt/g4-DM1 in relationship with the tumor regrowth curve (Fig. 5c). Zt/g4-DM1 in vivo has a terminal half-life (t½) of 6.01 days . The regrowth was found at day 44 for both H2228 and H358, and day 36 for T-47D- xenografts. The calculated TSCs were 2.02 mg/kg for H2228, 1.94 mg/kg for H358, and 6.25 mg/kg for T-47D cell-derived xenograft tumors, respectively. These results indicate that in vivo Zt/g4-DM1 at ~2 mg/kg is required to reach a tumoristatic status for H2228 and H358 cell-derived xenograft tumors. However, a relatively high TSC at ~6.25 mg/kg is necessary to balance the T-47D cell-derived tumor growth and inhibition.
To exclude any possibilities that reduction of tumor is related to general toxicity of Zt/g4- DM1 in vivo, we monitored body weight of individual tumor-bearing mice before and after treatment (Fig. 5d). All mice behaved normally and their body weight progressively increased during the entire observation period. Injection of cancer cells did not alter mouse growth curve. Significantly, Zt/g4-DM1 treatment did not halt mouse growth with increased body weight. The average body weight of experimental groups was comparable to that of control mice with no statistical differences. Thus, results in Fig. 5d demonstrate that tumor reduction is not related to the general toxicity of Zt/g4-DM1 on mouse growth.
Therapeutic effect of Zt/g4-DM1 in combination with chemotherapeutics
We first studied the activities of Zt/g4-DM1 in combination with chemotherapeutics. BC and NSCLC cell lines were treated for 96 h in vitro with different amounts of gemcitabine, Zt/g4-DM1 or their combinations at 1 to 1 molar ratio. Results in Fig. 6a show a progressive reduction of cell viability in both single and combination-treated groups in all five cancer cell lines tested. Analysis of data by plotting the fraction of inhibition against the combination index (Fig. 6b) confirmed a synergism between Zt/g4-DM1 and gemcitabine at the defined concentrations in five cancer cell lines tested. An interesting finding was in H2228 cells, in which a synergistic activity was only observed when the low concentration of two drugs were used (Fig. 6b).
We then performed the combination therapy in mouse xenograft tumors, in which Zt/g4- DM1 at 10 mg/kg in the Q8 × 2 regimen was combined with gemcitabine at 60 mg/kg in the Q4 × 4 schedule (Fig. 6c). Gemcitabine alone partialy inhibited H358 and T-47D xenograft tumors in a time-dependent manner with an average reduction in tumor volume at 51.3 and 73.8 % at day 36, respectively. Similarly, Zt/g4-DM1 alone also partially delayed the H358 and T-47D xenograft tumor growth at day 36 with an average 68.0 and 71.1 % reduction in tumor volume, respectively. The combination therapy resulted in a significant inhibition of H358 and T-47D xenograft tumors. An average growth inhibition in tumor volume with statistical difference (p: <0.05) was 88.43 % for H358 and 90.62 % for T-47D. Measurement of tumor weight at the end of the study further confirmed an increase in inhibition of tumor growth. For H358 xenograft tumors, the average tumor weight from the combined treatment groups (0.24 g ± 0.17) was significantly less than that from the Zt/g4-DM1-treated group (0.38 g ± 0.13, p <0.05) and from the gemcitabine-treated group (0.50 g ± 0.14, p <0.05) (Fig. 6d). Similar results also were observed in T-47D xenograft tumors, in which the average tumor weight from the combination group (0.16 g ± 0.09) was much less than Zt-g4-DM1 (0.59 g ±0.11) or gemcitabine (0.27 g ± 0.10) treated groups (p <0.05). Thus, Zt/g4-DM1 in combination with gemcitabine results in the increase in inhibition of T-47D and H358 xenograft tumors.
The study presented here shows the effectiveness of Zt/g4 in RON-targeted DM1 delivery for treatment of BC and NSCLC. Both in vitro and in vivo studies demonstrated the capability of Zt/g4 in induction of RON internalization by cancer cells. Also, Zt/g4-directed delivery of DM1 is sufficient to cause cell cycle arrest in G2/M phase, to inhibit cell proliferation and to cause massive cell death. These functional analyses help to establish a correlation between the IC50 values for cell viability and the levels of RON expression by cancer cells. Studies from mouse xenograft tumor models confirmed that Zt/g4 is suitable for DM1 delivery in vivo and Zt/g4-DM1 at 20 mg/kg in the Q12 × 2 regimen inhibits tumor growth with a long-lasting effect. The combinational therapy further demonstrated that Zt/g4-DM1 together with chemoagents results further in delaying BC and NSCLC xenograft tumor growth. Thus, Zt/g4-DM1 is effective in the model of anti-RON ADC for treatment of BC and NSCLC overexpressing the RON receptor tyrosine kinase.
Selection of Zt/g4 for DM1 conjugation and delivery is based on its unique feature in induction of RON internalization [25, 34]. We noticed that the kinetics of Zt/g4—induced RON internalization between BC and NSCLC cell lines are quite different. The IE50 values for BC cell lines expressing the high levels of RON (more than 8000 RON molecules per cell) is in the range of 10 ~ 16 h. In contrast, the IE50 values for NSCLC H2228 and H358 cell lines expressing similar levels of RON were at the 7 to 10 h ranges. The mechanism(s) underlying such differences currently is unknown. Regardless of the difference, Zt/g4-induced RON internalization is highly effective with more than 85 % of cell surface RON internalized within 36 h. In the case of H358 cells expressing ~15,000 RON molecules per cell, it translates into 12,750 RON receptors that are internalized within 36 h. This is equivalent to 51,000 DM1 molecules delivered into a single cell, which is sufficient to cause cell cycle arrest. In cell lines such as H1993 expressing the low level of RON, Zt/g4 was able to induce RON internalization with IE50 similar to those of other cancer cell lines (Fig. 1b). However, the amount of internalized payload is significantly less by calculation due to the low levels of the RON expression. Considering the fact that normal epithelial cells express low levels of RON, we reason that the low density of RON in normal epithelial cells is not enough to bring sufficient amount of DM1 to cause significant biological activity. Results in Fig. 2 appear to support this notion. Thus, Zt/g4-induced RON internalization facilitates intracellular delivery of DM1 in cancer cells expressing high levels of RON.
The action of DM1 delivered by Zt/g4 was displayed in both BC and NSCLC cells. First, we showed by flow cytometric analysis that the Zt/g4-DM1 internalization causes cell cycle arrest in G2/M phase, which is a feature of DM1 that impairs microtubule dynamics . This effect was observed as early as 6 h after the addition of Zt/g4-DM1 and characterized by progressive reduction of the G1 phase and the accumulation of cells at the G2/M phase. Second, we found that Zt/g4-directed DM1 delivery progressively decreases cell viability. More than 80 % reduction in cell viability 96 h after treatment was achieved among three BC and two NSCLC cell lines tested. Third, we documented a massive cell death in Zt/g4-DM1-treated BC and NSCLC cells in a dose-dependent manner with Zt/g4-DM1 IC50 values ranging from 2 to 6 μg/ml. Analysis of cellular markers for apoptotic death further confirmed that Zt/g4-DM1 treatment activates PARP as evident by the presence of the PARP fragment. These findings indicate that DM1-mediated cell cycle arrest leads to initiation of an intracellular apoptotic pathway. Finally, we discovered that the efficacy of Zt/g4-DM1 in vitro directly correlates with the levels of the RON expression by cancer cells. For Zt/g4-DM1 to achieve a significant reduction in cell viability, the minimal RON molecule expressed by cancer cells should be at ~8000 receptors per cells. We reason that such a correlational relationship is useful for predicting the in vitro effectiveness of Zt/g4-DM1 against cancer cells, which helps to select potential target cancer cells for evaluation in vivo.
Results from mouse xenograft tumor models demonstrate the efficacy of Zt/g4-DM1 in inhibition of tumor growth. It is possible that Zt/g4-mediated immunological activities may also contribute the observed therapeutic efficacy. As described in other ADCs, antibody-dependent cell-mediated cytotoxicity, antibody dependent cellular phagocytosis, and complement- dependent cytotoxicity play a role in vivo in the ADC anticancer activity . We used Zt/g4- DM1 at 20 mg/kg in the Q12 × 2 regimen for the animal study. This dosing regimen was designed to determine whether Zt/g4-DM1 at a total of 40 mg/kg in a particular period is sufficient to inhibit tumor growth. We showed that the action of Zt/g4-DM1 is dependent on levels of the RON expression. Zt/g4-DM1 effectively inhibited xenograft tumor growth mediated by H228, H358, and T-47D cells but has no effect on H1993 cell-mediated tumors. By applying pharmacokinetic data of Zt/g4-DM1, we monitored Zt/g4-DM1 efficacy for several half-life cycles, which confirms that Zt/g4-DM1 has the long-lasting effect of up to 2 weeks without signs of tumor regrowth (from day 24 to day 40 in the NSCLC model and from day 24 to day 36 in the BC model) (Fig. 5a). Moreover, we established the TSC as the indicator of Zt/g4-DM1 for monitoring xenograft tumor growth, which should help us to predict the dose-response curve and to design the treatment regimen for further study [41, 42]. Finally, we observed that the Zt/g4-DM1 regimen used in vivo did not exert significant toxicity towards animals. An increase in the average body weight was observed in Zt/g4-DM1 treated animals. Considering these facts, we conclude that Zt/g4-DM1 is effective and safe in the targeted treatment of BC and NSCLC xenograft tumors.
Studies using H358 and T-47D xenograft models demonstrated the increase in therapeutic activity between Zt/g4-DM1 and gemcitabine in inhibition of tumor growth. We showed from in vitro studies that the combination of Zt/g4-DM1 with chemotherapeutics at the same molar ratio further reduce viability of BC and NSCLC cells. Analysis of the average tumor weight at the end of the study also confirmed the increase in therapeutic activity between Zt/g4-DM1 and chemotherapeutics. This indicates that the inhibition can be synergized through different mechanisms of action. It is worth to note that the synergism of Zt/g4-DM1 with gemcitabine is dependent on individual cancer cell lines in the particular dose range. We reasoned from the combination therapy that since BC and NSCLC tumors are highly malignant at the later stage, Zt/g4-DM1 in combination with chemotherapeutics could be a strategy for targeted cancer therapy.
We present evidence in this study that anti-RON antibody directed delivery of the highly potent drug DM1 in the form of ADC is a therapeutic strategy for targeted treatment of breast and NSCLC cancer in animal models. Results from various in vitro and in vivo experiments showed that Zt/g4-DM1 not only significantly decreases viability of breast cancer and NSCLC cells but also dramatically delays the tumor growth in mouse xenograft tumor models. Moreover, we demonstrated that Zt/g4-DM1 in combination gemcitabine significantly increases the inhibitory effect on xenograft tumor growth. These findings lay the foundation for clinical development of anti-RON ADC Zt/g4-DM1 for potential cancer therapy.
antibody-dependent cell- mediated cytotoxicity
antibody-dependent cellular phagocytosis
American type cell culture
hydrophobic interaction chromatography
lysosomal-associated membrane protein-1
lymphocyte antigen 6 complex, locus E
non-small cell lung cancer
Recepteur d’Origine Nantais
poly ADP ribose polymerase
tyrosine kinase inhibitor
therapeutic monoclonal antibody
Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21:5–13.
Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389–97.
Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.
Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57:6949–64.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.
de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, Koti K, Rothmann M, Shapiro M, Borrego F, Clouse K, Chen XH, Brown J, Akinsanya L, Kane R, Kaminskas E, Farrell A, Pazdur R. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18:5845–9.
Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. 2011;10:1728–39.
Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12:2591–6.
Damelin M, Bankovich A, Park A, Aguilar J, Anderson WC, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz MA, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ. Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin Cancer Res. 2015. Epub ahead of print.
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721–9.
Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29:1578–86.
Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi D-A, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinomas overexpressing trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106–16.
Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, Firestein R. An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies. Clin Cancer Res. 2015;21:3252–62.
Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8:1195–202.
Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON signaling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 2013;13:466–81.
Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC, Vasiliauskas J, Plattner R, Wang YL, Wang SC. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene. 2014;33:1429–37.
Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Short-form Ron promotes spontaneous breast cancer metastasis through interaction with phosphoinositide 3-Kinase. Genes Cancer. 2011;2:753–62.
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014;74:884–95.
Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non- small cell lung cancers. Genes Chromosomes Cancer. 2012;51:841–51.
Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998;16:2927–33.
Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co- expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005;11:2222–8.
Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J Pathol. 2007;213:402–11.
Yao HP, Zhuang CM, Zhou YQ, Zeng JY, Zhang RW, Wang MH. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor. Curr Cancer Drug Targets. 2013;13:686–97.
Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R, Wang MH. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res. 2014;20:6045–58.
O’Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 2006;66:9162–70.
Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, et al. Discovery of N-(4-(2- amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2- dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem. 2009;52:1251–4.
Raeppel SL, Raeppel F, Therrien E. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. Bioorg Med Chem Lett. 2015;25:2527–31.
Northrup AB, Katcher MH, Altman MD, Chenard M, Daniels MH, Deshmukh SV, Falcone D, Guerin DJ, Hatch H, Li C, Lu W, Lutterbach B, Allison TJ, Patel SB, Reilly JF, Reutershan M, Rickert KW, Rosenstein C, Soisson SM, Szewczak AA, Walker D, Wilson K, Young JR, Pan BS, Dinsmore CJ. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5] cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c- Met. J Med Chem. 2013;56:2294–310.
Guin S, Yao HP, Wang MH. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm. 2010;7:386–97.
Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP, Wang MH. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer Chemother Pharmacol. 2011;67:1073–83.
Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R, Wang MH. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm. 2011;8:2310–9.
Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther. 2006;5:1179–86.
Li Z, Yao H, Guin S, Padhye SS, Zhou YQ, Wang MH. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol. 2010;37:473–82.
Brun MP, Gauzy-Lazo L. Protocols for lysine conjugation. Methods Mol Biol. 2013;1045:173–87.
Sharma S, Zeng JY, Zhuang CM, Zhou YQ, Yao HP, Hu X, Wang MH. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther. 2013;12:725–36.
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22 Suppl 11:3–10.
Saveria M, Montani G, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res. 2013;32:95–105.
Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, Ma J. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9:2689–99.
Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski M, Fielder PJ, Tibbitts J. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate in mice. J Pharmacokinet Pharmacodyn. 2010;37:221–42.
Wang H, Rangan VS, Sung MC, Passmore D, Kempe T, Wang X, Thevanayagam L, Pan C, Rao C, Srinivasan M, Zhang Q, Gangwar S, Deshpande S, Cardarelli P, Marathe P, Yang Z. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos. 2015. doi:10.1002/bdd.1953. Epub ahead of print.
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–81.
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.
We greatly appreciate the assistance of Ms. Susan Denney (Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX) in editing the manuscript. This work was supported in part by NIH grant R01 CA91980 (MHW), Cancer Research funds from the Amarillo Area Foundation (MHW), and by Zhejiang Major Medical Health & Sciences Technology Foundation Projects #WKJ-ZJ-13 and #2014C33204 (HPY). RZ was supported by NIH grants R01 CA112029 and CA121211 and JZ was supported by Natural Science Foundation of China (81161120537).
The authors confirm that there are no known conflicts of interest associated with this publication. The manuscript has been read and approved by all authors and there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of authors. All animal works presented in this study has been approved by TTUHSC Institutional Animal care & Use Committee, which is acknowledged within the manuscript.
LF and HPY contribute equally to this work. LF was involved in preparation of antibody-drug conjugation, some in vitro and in vivo studies related to NSCLC. SS was involved in antibody characterization, some in vitro studies related to breast cancer. HPY and YQZ produced and purified anti-RON antibody, participated in some in vitro experiment, analyzed data, and provided partial funds for this project. JWZ provided experimental design and technical support for some intro experiments. RWZ was participated experimental design for combination study. MHW designed the study, participated in data analysis, wrote the manuscript, and secured the fund for completion of this study. All authors read and approved the final manuscript.
About this article
Cite this article
Feng, L., Yao, HP., Sharma, S. et al. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res 35, 70 (2016). https://doi.org/10.1186/s13046-016-0347-6
- Antibody-drug conjugate
- Breast cancer
- Lung cancer
- Receptor tyrosine kinase
- Therapeutic efficacy
- Combination therapy